Odanacatib (ODN) is a selective, potent and reversible inhibitor of cathepsin K (CatK) that
inhibits bone loss in postmenopausal osteoporosis. Evidence from osteoclast (OC) formation …

The cathepsin K (CatK) inhibitor odanacatib (ODN) is currently being developed for the
treatment of osteoporosis. In clinical trials, efficacy and resolution of effect of ODN treatment …

Osteoporosis is a metabolic bone disease that is characterized by heightened state of bone
resorption accompanied by diminished bone formation, leading to a reduction of bone …

Cathepsin K (CatK), a cysteine protease, is highly expressed by osteoclasts and very
efficiently degrades type I collagen, the major component of the organic bone matrix. Robust …

Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption
over bone formation, resulting in decreased bone mineral density and deterioration of bone …

Cathepsin K is a key enzyme involved in the degradation of organic bone matrix by
osteoclasts. Inhibition of bone resorption observed in human and animal models deficient for …

Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …

Odanacatib (MK· 0822, MK-822) is an orally administered cathepsin K inhibitor being
developed by Merck & Co Inc, under license from Ce/era Croup, for the treatment of …

Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and
localized in the lysosomes and resorption lacunae of these cells. CatK is the principal …

Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen.
Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone …